In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.
Micromet Signs $477M Deal with Sanofi-Aventis
Micromet has licensed one of its cancer-fighting antibody candidates to Sanofi-Aventis in a $477 million deal.
